Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pragmatic Eight Week Phase IV Study of Bamlanivimab/LY-CoV555 for Emergency Passive Immunity Against COVID-19

NCT04796402 is registered in ClinicalTrials.gov with Fraser Health as lead sponsor.

NCT NCT04796402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04796402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pragmatic Eight Week Phase IV Study of Bamlanivimab/LY-CoV555 for Emergency Passive Immunity Against COVID-19
Lead sponsor
Fraser Health
Phase
Phase 4
Overall status
Unknown status
Start date
March 17, 2021
Completion date
December 31, 2021
Enrollment
576 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19